Coastlands Capital LP has made a notable update regarding its ownership structure, as detailed in a recent SEC filing. The company reported that on November 2, 2026, shares of Series A Non-Voting Convertible Preferred Stock were automatically converted into common stock of Azora Therapeutics, Inc. This conversion has resulted in Coastlands Capital LP ceasing to beneficially own more than 10% of the outstanding common stock of Azora Therapeutics, thus removing it from the obligations of Section 16 reporting.

This change is significant for Coastlands Capital LP as it reflects a strategic shift in its investment approach. By no longer holding a controlling stake in Azora Therapeutics, the firm may be repositioning its assets or focusing on other investment opportunities. This could also suggest a broader trend within the pharmaceutical preparations industry, where companies are continually reassessing their capital structures and investment strategies.

Background

Coastlands Capital LP is an investment firm based in San Francisco, California. The company specializes in managing investments and has been active in various sectors, including life sciences. The recent filing indicates that Coastlands Capital LP is involved in significant transactions related to its holdings in Azora Therapeutics, Inc., which operates in the pharmaceutical preparations sector. The firm has filed several documents with the SEC, including recent Schedule 13G/A filings, indicating ongoing adjustments in its investment positions.

What the Filing Says

The SEC filing reveals that Coastlands Capital LP, as of November 2, 2026, holds 388,308 shares of common stock in Azora Therapeutics, following the conversion of preferred stock. The filing states, "As a result of such conversion, the Reporting Persons ceased to beneficially own more than 10% of the outstanding common stock." This change means that Coastlands is no longer subject to Section 16 reporting requirements.

Impact

This development may affect various stakeholders, including investors and analysts monitoring Coastlands Capital LP and Azora Therapeutics. The reduction in ownership stake could lead to changes in how both companies are perceived in the market. For Azora Therapeutics, this shift may impact its stock performance and investor confidence, especially if other shareholders react to the change in ownership dynamics.

What's Next

The filing does not say what happens next for Coastlands Capital LP or its future investment strategies. However, the firm’s recent activity suggests that it may continue to adjust its holdings in response to market conditions and investment opportunities.